ILA

ISLAND PHA FPO [ILA]
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company's lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
Healthcare · ASX Small Cap
$0.4400 +0.0%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when ILA triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track ILA — Free

Active Signals

Bullish Signals

  • Stochastic is deep in oversold territory — bounce conditions forming
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Trading above the 200-day average — the long-term trend is on your side
  • Strong cash runway (11 quarters)
  • Very high P/S ratio (460.9x)
  • Strong revenue growth (+996%)
  • EPS estimates revised upward (+10pts)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +996% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (5.51%/day)
  • Altman Z-Score distress zone (1.80 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Not enough chatter to gauge sentiment — defaulting to neutral
Ask Scout AI about ILA
"What's driving ILA today?" "How does ILA compare to peers?" "Key risks for ILA?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Pivotal Marburg data secured for Galidesivir FDA pathway
NONE Appendix 4G and Corporate Governance Statement
NONE Preliminary Final Report
LOW Annual Report to shareholders

Recent ASX Announcements

2026-08-30 Pivotal Marburg data secured for Galidesivir FDA pathway PRICE SENSITIVE
2026-08-26 Appendix 4G and Corporate Governance Statement
2026-08-26 Annual Report to shareholders
2026-08-26 Preliminary Final Report PRICE SENSITIVE
2026-08-20 Island boosts Galidesivir supply as Ebola surges PRICE SENSITIVE

Key Metrics

$130.3M
Market Cap
141K
Avg Volume
1.2x
Vol Ratio
$0.20 — $0.63
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-95.5%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 51%
LLeader vs LaggardpassRS: 8
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:ILA vs REGILA vs CANILA vs BIT
Scout Pro — Deeper Analysis for ILA
Try Pro free for 30 days
Share this analysis

Track ILA and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required